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Aims: Relationship between liver enzymes such as gamma-glutamyl transferase (GGT), alanine 
aminotransferase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) and risk 
of gestational diabetes mellitus (GDM) is a controversial issue. The aim of this systematic review 
and dose-response meta-analysis was investigation the association between liver enzymes and 
risk of GDM in observational studies. 
 
Methods: A Comprehensive systematic literature search was conducted in MEDLINE/PubMed, 
SCOPUS, and Web of Science databases up to September 2019. Combined odds ratios (ORs) 
with 95% confidence intervals (CIs) were evaluated by DerSimonian and Laird random-effects 
models. Dose-response analyses of these relationships were also carried out. 
 
Results: Eight studies with 25,451 participants containing 2,549 cases were included in this study. 
 
Pooled results showed a significant association between GGT levels and risk of GDM (OR: 2.10, 
95% CI: 1.14-3.86, I2: 84%). In addition, random-effects model indicated a dramatic and direct 
significant association between GGT and risk of GDM in non-linear (p<0.001) and linear (p<0.001) 
dose-response analysis. Associations between ALT and AST with risk of GDM were found to be 
non-significant (OR: 1.32, 95% CI: 0.91-1.90, I2: 65% and OR: 0.76, 95% CI: 0.52-1.10, I2: 16%, 
respectively). 
 
Conclusions: This systematic-review and dose-response meta-analysis highlights GGT as a 












Gestational diabetes mellitus (GDM) represents a significant health concern for both prospective 
mothers and their fetuses. Mothers are at risk of experiencing serious GDM-related gestational, 
perinatal and postnatal complications, including hypertension, obstetric complications and 
subsequent development of type-2 diabetes mellitus (T2DM). In turn, the GDM-exposed infant is 
at risk of developing macrosomia with subsequent birth trauma or hypoglycemia in the perinatal 
period [1]. In addition, long-term complications for the offspring include increased risk of metabolic 
syndrome and neonatal respiratory distress syndrome [2-4] and, potentially, impaired academic 
achievement [5]. A wide range in the incidence of GDM is often reported in the literature, which 
is generally attributed to disparities in diagnostic criteria between organizations; however, rates 
of between 6-7% of pregnancies are often cited previously, depending on the populations 
assessed [6, 7]. With obesity rates on a concerning upward trajectory globally and an increasing 
prevalence of geriatric mothers, the rates of GDM appear to be rising in concert in a diversity of 
cohorts [8, 9]. More recent estimates from the International Diabetes Federation suggest that 
there were 18.4 million cases of GDM-induced hyperglycemia in 2017 [10], which puts the current 
predicted rate at ~14%. 
 
The early detection of GDM through screening programs is essential to the effective treatment 
of the disease and prevention of the aforementioned sequelae [11]. In many countries, prospective 
mothers will undergo clinical screening for risk factors of GDM at a first trimester antenatal booking 
visit, with subsequent testing by random blood glucose, fasting blood glucose or oral glucose tolerance 
test if pertinent risk factors are identified. However, such investigations are often costly and time-
consuming, with inadequate sensitivity in the case of random blood glucose testing [12]. This is 
particularly pertinent in the context of low and middle-income countries, where GDM rates appear to 





testing and treatment funds may not be available [14]. Therefore, an alternate cost-effective 
means of screening is currently of paramount importance in this context. 
 
Non-alcoholic fatty liver disease (NAFLD) is a common complication of obesity and is 
associated with the metabolic dysfunction and insulin resistance observed in the phenotype [15]. 
In addition, abnormal liver enzyme profiles have demonstrated potential as initial biochemical 
markers of hepatic fatty deposition [16]. In line with this, several studies have investigated the 
utility of such markers as predictors of the development of diabetes and other disease[17, 18], 
with GGT appearing to provide the most robust association [19]. Therefore, it is perceivable that 
alterations in circulating liver enzyme levels may represent a reliable indicator of the metabolic 
dysfunction which predisposes mothers to the development of GDM. However, there remains a 
degree of discord amongst the literature examining this hypothesis. The present systematic 
review and meta-analysis aimed to synthesize the available observational data assessing the 
putative relationship between GDM and individual liver enzymes, GGT, ALT, ALP and AST. In 
addition, a dose response analysis was conducted to assess the nature and magnitude of the 





Materials and Methods 
 
 
MOOSE guidelines (Recommendations of the Meta-analysis Of Observational Studies in 
Epidemiology) were followed to conduct of this systematic-review and dose-response meta-
analysis [20]. A comprehensive literature searches was conducted in PubMed/MEDLINE, 
Scopus, and Web of Science databases for observational studies that examine association 
between liver enzymes and GDM from inception to September 2019 without language or time 
limitations. The search strategy contained MESH and title/abstract format of “liver enzyme” AND 





alert service was activated to avoid any missing novel articles published after our comprehensive 
literature search. Furthermore, references of relevant papers were scrutinized to identify 
additional studies that may not have been identified through our systematic search. 
 
Inclusion criteria, data extraction and quality assessment 
 
 
The following inclusion criteria were applied: 1) observational design; 2) reported relation between 
liver enzyme and GDM in appropriate format (hazard ratio (HR), risk ratio (RR), or odd ratio (OR) and 
the corresponding 95% confidence intervals (CI)). We contacted corresponding authors for further 
information in papers with missing data. The studies with reviews and editorial design or non-human 
studies, case reports, and letters to editor were excluded from this study. 
 
Studies were screened and data were extracted by two independent authors and 
discrepancies were resolved through the senior author. The following data were extracted: the first 
authors’ name, year of publication, study location, design of study, total number of participants and 
cases, mean age of participants, time during pregnancy when liver enzymes were evaluated, 
confounding factors, summary estimates and 95% CIs of GDM incidence. We assessed the quality of 





The STATA 14.0 statistical software (Stata Corporation, College Station, Texas, USA) was used for 
statistical analysis of the dataset. Combined risk estimates of GDM incidence was evaluated using 
DerSimonian and Laird random-effects model [22]. Heterogeneity between studies was estimated 
using the Cochrane Q test and I2 statistic with a significant cut point of 0.1 for Cochrane Q test and 
50% for I2 statistic. Restricted cubic splines (with three knots at percentiles 10%, 50%, and 90%) was 
used to evaluate curvilinear association between liver enzymes and risk of GDM [23]. Funnel plot, 

















Figure 1 presents a flow diagram of literature database research. In our primary systematic 
search, 261 records were identified from PubMed/MEDLINE, Scopus, and Web of Science 
databases. From these, 122 were excluded as duplicates and 121 were excluded as irrelevant 
based on the title and/or abstract. Eighteen studies were evaluated in full text screening and 10 
studies failed to meet inclusion criteria and were subsequently excluded. Finally, eight studies 
with a total of 25,451 participants were identified as eligible according to meta-analysis inclusion 
criteria [24-31]. 
 
Study characteristics and quality assessment 
 
 
The selected characteristics of the eight included studies are presented in Table 1. No patients in 
the last two studies with similar first author name participated in both studies. All studies were 
published between 2008 to 2019. Three of the studies were performed in US [25, 27, 29], three 
in China [24, 26, 28], and two in Malaysia [30, 31]. Three studies had a prospective design and 
three were case-control studies. The mean age of participants was 29 years. Totally 2,549 cases 
and 25,451 participants were included in the analysis. The quality of included studies was 
evaluated by Newcastle-Ottawa Quality Assessment scale and most were found to be of good 
quality (Supplemental Table 2). Adjusted covariates presented in Supplemental Table 3. 
 





Five studies provided data from 5,709 participants containing 965 cases for GGT [25, 26, 29-31]. 
The pooled OR (95% CI) in the highest category versus the lowest category of GGT was (OR: 
2.10, 95% CI: 1.14-3.86, I2: 84%) for risk of GDM (Figure 2). This OR means if we have 10 
pregnancies with normal GT who developed gestational diabetes in total 1000 pregnancies with 
normal GT, there will exist 21 pregnancies with elevated GT who developed gestational diabetes 
in total 1000 pregnancies with elevated GT. 
 
We pooled data from five studies containing six arms with 21,728 participants and 2,190 
cases by random effect models [25, 27-30]. Combined results did not reveal a significant 
association with GDM in highest category of ALT compared to lowest category (OR: 1.32, 95% 
CI: 0.91-1.90, I2: 65%). 
 
Pooled results of included studies did not demonstrate a significant relationship between 
AST levels and OR for GDM (OR: 0.76, 95% CI: 0.52-1.10, I2: 16%)[29, 30]. Furthermore, just 
one study was identified that evaluated the relationship between ALP and GDM [24] and we could 
therefore conduct an analysis; however, according to Xiong et al., there is a significant relation 
between ALP levels and OR for GDM 2.47 (95% CI 1.47, 4.15) in highest category of ALP 





The linear dose-response relationship between GGT, ALT, and AST and non-linear dose-
response relationship between GGT and ALT with risk of GDM were evaluated. The pooled OR 
from the random-effects model indicated a dramatic direct significant association between GGT 
and risk of GDM in non-linear (p<0.001) and linear (p<0.001) dose-response analysis (Figure 3). 
This relationship was found to be direct and significant between ALT and GDM in the linear 





response analysis. Finally, the relationship between AST and GDM was not significant in the 




No significant asymmetry was identified amongst included studies through Funnel Plotting (Figure 4). 
Additionally, Begg’s and Egger’s test did not identify publication bias (Begg’s p=0.62 and Egger’s 








The relationship between liver enzymes, such as gamma-glutamyl transferase (GGT), alanine 
aminotransferase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) and risk of 
gestational diabetes mellitus (GDM) has yielded equivocal results in the literature. However, given 
that up to 70% of women with GDM go on to develop Type 2 diabetes, with a very large increase in 
incidence within the first five years, which is related with innumerable injurious health consequences 
[32-35]. Thus, it would be pragmatic to assimilate and analyze all contemporary evidence, in an effort 
to better inform clinicians, the public and other key stakeholders. Therefore, the aim of this systematic 
review and dose-response meta-analysis was investigation the association between liver enzymes and 
risk of GDM in observational studies. In accord with the aforementioned aim, pooled results showed 
a significant association between GGT levels and risk of GDM. Furthermore, a direct and significant 
association between GGT and risk of GDM was evident in non-linear (p<0.001) and linear (p<0.001) 
dose-response analyses. However, the association between ALT and AST, and risk of GDM, were non-
significant, respectively. 
 
Our findings with GGT are consistent with empirical research examining liver enzymes and 





development, and onset, of type 2 diabetes [36-38]. The relationship between GGT and, particularly, 
type 2 diabetes has been shown to manifest in a dose-response manner [37], whilst also being 
independent of other, recognized, diabetes risk factors [39]. For instance, Gao et al reported that GGT 
concentrations were related to risk of prediabetes and positively associated with insulin resistance, 
independently[40]. There is a paucity of literature that as examined liver enzyme levels during 
pregnancy, particularly with regards to GDM risk, and in instances it has been investigated, literature 
reported findings have been equivocal. Interestingly, in the absence of a hepatitis diagnosis, increased 
GGT levels is regarded to represent excess fat deposition in the liver [41], which is accepted to be 
characterized by insulin resistance [40]. Importantly, laboratory tests for GGT, ALT and AST are 
commonly utilised to assess the overall health of the liver, with results shown to correlate with features 
of insulin resistance independent of BMI and central obesity. While the de facto standard for measuring 
for a variety liver diseases is to perform a liver biopsy, testing of ALT, AST, and GGT demonstrably 
provides reasonable noninvasive surrogate measures [42]; and therein, given we highlighted the 
relationship between GGT and GDM, routine measurement of GGT may represent a viable and 





The liver is essential in maintaining, during both fasted and postprandial states. glucose homeostasis, 
and thus represents a fundamental tent of type 2 diabetes development. Serum levels of GGT is also 
asserted to represent a marker of oxidative stress [43, 44], which is defined by increased free radicals’ 
presence and lipid oxidation. Moreover, oxidative stress may play a role in type 2 diabetes etiology, 
primarily through inducing insulin resistance and impairing insulin secretion [45, 46]. GGT is shown 
to catabolize extracellular glutathione (GSH), which possesses an antioxidant role, thus, in response to 





to produce more GSH [47]. Elevations in GGT levels may lead to increased permeation of the 
GSH tripeptide into cells, where it can act to protect against oxidative damage [48]. It has been 
speculated that GGT level may also represent a marker of exposure to environmental pollutants 
[49], which may be present in adipose tissue, perturb endocrine processes, and may further interact 
with obesity to negatively influence diabetes risk. In addition, it has been suggested that elevated 
liver enzymes may reflect underlying chronic inflammation, conceivably impairing insulin 
signaling [50, 51]. However, although we demonstrate the significant relationship between GGT 
and GDM, the mechanisms by which GGT influences, mediates, or contributes to the development 
of GDM must be investigated in greater detail. 
 
With respect to AST and ALT, respectively; AST exists throughout the body and it elevation can 
manifest in a multitude of clinical pathologies [52]; furthermore, its’ association with diabetes 
appears tenuous [53]. ALT is, primarily, found within the liver, and is believed to represent a 
biomarker of liver fat accumulation [54]. The non-significant association between ALT and GDM 
in the current study is somewhat surprising, particularly given that ALT is considered a risk marker 
for type 2 diabetes [53]; however, several, independant studies have reported no association 
between ALT and diabetes [55, 56]. 
 
Strength and limitations 
 
The main strength of this study is the incorporation of a large sample size, consisting of over 
25,000 participants. This provided findings that are generalizable and facilitated the opportunity for 
dose-response analysis. Visual inspection of the funnel plot and, indeed, formal statistical testing 
yielded no indication of publication bias, which is a clear improvement in the reliability of our results, 
compared to previous meta-analyses, where significant heterogeneity was reported [57]. We found that 





and thus, we can conclude that the results of this meta-analysis are unlikely to be biased by a selective 
lack of unpublished, or grey literature, studies. Whilst the sample amalgamated in the present study is 
large; the results do not necessarily yield definitive findings of a causal inference; thus, it must be 





This systematic-review and dose-response meta-analysis highlights that GGT may represent a 
significant, clinically relevant, predictor related to the incidence of gestational diabetes mellitus. 
There was no evidence for an increased risk of GDM with AST or ALT level. Thus, we assert that 
further longitudinal studies long-term follow-up and repeat measurements are still warranted to 
avow the magnitude and direction of these associations, in addition to permitting greater clinical 
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